Given our data linking ZFP36L1 to the inflammatory subtype of SCLC, which is more responsive to ICB, it is possible that LSD1 inhibition could cooperate with ICB in SCLC. The gene discussed is ZFP36L1; the disease is small cell lung carcinoma.